Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of
PM02734 administered in combination with erlotinib to determine the safety and tolerability
and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the
combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.